ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012

McMurray, John J.V.; Adamopoulos, Stamatis; Anker, Stefan D.; Auricchio, Angelo; Böhm, Michael; Dickstein, Kenneth; Falk, Volkmar; Filippatos, Gerasimos; Fonseca, Cândida; Gómez-Sánchez, Miguel Ángel; Jaarsma, Tiny; Køber, Lars; Lip, Gregory Y.H.; Maggioni, Aldo P.; Parkhomenko, Alexander; Pieske, Burkert; Popescu, Bogdan A; Rønnevik, Per K.; Rutten, Frans H.; Schwitter, Juerg; Seferović, Petar; Stępińska, Janina; Trindade, Pedro T.; Voors, Adriaan A.; Zannad, Faı̈ez; Zeiher, Andreas M.; Bax, Jeroen J.; Baumgartner, Helmut; Ceconi, Claudio; Dean, Veronica; Deaton, Christi; Fagard, Robert; Funck‐Brentano, Christian; Hasdai, David; Hoes, Arno W.; Kirchhof, Paulus; Knuuti, Juhani; Kolh, Philippe; McDonagh, Theresa A.; Moulin, Anne‐Marie; Reiner, Željko; Sechtem, Udo; Sirnes, Per Anton; Tendera, Michał; Torbicki, Adam; Vahanian, Alec; Windecker, Stephan; Bonet, Luis Almenar; Avraamides, Panayiotis; Lamin, Hisham A. Ben; Brignole, Michele; Coca, António; Cowburn, Peter J.; Dargie, Henry J.; Elliott, Perry; Flachskampf, Frank A.; Guida, Guido Francesco; Hardman, S. M. C.; Iung, Bernard; Merkely, Béla; Müeller, Christian; Nanas, John N.; Nielsen, Olav Wendelboe; Ørn, Stein; Parissis, John; Ponikowski, Piotr

doi:10.1093/eurjhf/hfs105

Cited by 2,121 publications

(808 citation statements)

References 282 publications

(273 reference statements)

Supporting

Mentioning

774

Contrasting

Unclassified

Order By: Relevance

“…MI prevalence is 4.0% for men and 1.8% for women 1. According to investigation of the European Society of Cardiology, one in six men and one in seven women in Europe will die from MI 2. After occlusion of a coronary artery or its branch, necrosis of myocardium triggers local inflammation, scar formation and remodelling of the ventricular wall.…”

Section: Introductionmentioning

confidence: 99%

Mesenchymal stem cell‐loaded cardiac patch promotes epicardial activation and repair of the infarcted myocardium

Wang

et al. 2017

J Cellular Molecular Medi

View full text Add to dashboard Cite

Cardiac patch is considered a promising strategy for enhancing stem cell therapy of myocardial infarction (MI). However, the underlying mechanisms for cardiac patch repairing infarcted myocardium remain unclear. In this study, we investigated the mechanisms of PCL/gelatin patch loaded with MSCs on activating endogenous cardiac repair. PCL/gelatin patch was fabricated by electrospun. The patch enhanced the survival of the seeded MSCs and their HIF‐1α, Tβ4, VEGF and SDF‐1 expression and decreased CXCL14 expression in hypoxic and serum‐deprived conditions. In murine MI models, the survival and distribution of the engrafted MSCs and the activation of the epicardium were examined, respectively. At 4 weeks after transplantation of the cell patch, the cardiac functions were significantly improved. The engrafted MSCs migrated across the epicardium and into the myocardium. Tendency of HIF‐1α, Tβ4, VEGF, SDF‐1 and CXCL14 expression in the infarcted myocardium was similar with expression in vitro. The epicardium was activated and epicardial‐derived cells (EPDCs) migrated into deep tissue. The EPDCs differentiated into endothelial cells and smooth muscle cells, and some of EPDCs showed to have differentiated into cardiomyocytes. Density of blood and lymphatic capillaries increased significantly. More c‐kit+ cells were recruited into the infarcted myocardium after transplantation of the cell patch. The results suggest that epicardial transplantation of the cell patch promotes repair of the infarcted myocardium and improves cardiac functions by enhancing the survival of the transplanted cells, accelerating locality paracrine, and then activating the epicardium and recruiting endogenous c‐kit+ cells. Epicardial transplantation of the cell patch may be applied as a novel effective MI therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Mesenchymal stem cell‐loaded cardiac patch promotes epicardial activation and repair of the infarcted myocardium

Wang

et al. 2017

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…The beneficial effects of oral MRA therapy have been confirmed in subsequent clinical trials 20, 21, 39. The American27 and European29 guidelines now recommend eplerenone for all patients presenting with an AMI, LV dysfunction (LVEF ≤40%), and HF symptoms or DM. Therefore, it is anticipated that about 10% of the trial participants will meet these criteria and will go on open‐label MRA therapy, and this has been taken into account in the sample‐size calculation.…”

Section: Discussionmentioning

confidence: 91%

“…The study protocol will ensure optimal medical therapy for all study participants according to current practice guidelines 3, 27, 28, 29. Therefore, patients with a left ventricular ejection fraction (LVEF) ≤40% on the initial CMR scan and evidence of HF or who have diabetes mellitus (DM) will be started on open‐label eplerenone according to current practice guidelines.…”

Section: Methodsmentioning

confidence: 99%

Mineralocorticoid Receptor Antagonist Pretreatment to MINIMISE Reperfusion Injury After ST‐Elevation Myocardial Infarction (The MINIMISE STEMI Trial): Rationale and Study Design

Bulluck

Fröhlich

Mohdnazri

et al. 2015

Clinical Cardiology

View full text Add to dashboard Cite

Novel therapies capable of reducing myocardial infarct (MI) size when administered prior to reperfusion are required to prevent the onset of heart failure in ST‐segment elevation myocardial infarction (STEMI) patients treated by primary percutaneous coronary intervention (PPCI). Experimental animal studies have demonstrated that mineralocorticoid receptor antagonist (MRA) therapy administered prior to reperfusion can reduce MI size, and MRA therapy prevents adverse left ventricular (LV) remodeling in post‐MI patients with LV impairment. With these 2 benefits in mind, we hypothesize that initiating MRA therapy prior to PPCI, followed by 3 months of oral MRA therapy, will reduce MI size and prevent adverse LV remodeling in STEMI patients. The MINIMISE‐STEMI trial is a prospective, randomized, double‐blind, placebo‐controlled trial that will recruit 150 STEMI patients from four centers in the United Kingdom. Patients will be randomized to receive either an intravenous bolus of MRA therapy (potassium canrenoate 200 mg) or matching placebo prior to PPCI, followed by oral spironolactone 50 mg once daily or matching placebo for 3 months. A cardiac magnetic resonance imaging scan will be performed within 1 week of PPCI and repeated at 3 months to assess MI size and LV remodeling. Enzymatic MI size will be estimated by the 48‐hour area‐under‐the‐curve serum cardiac enzymes. The primary endpoint of the study will be MI size on the 3‐month cardiac magnetic resonance imaging scan. The MINIMISE STEMI trial will investigate whether early MRA therapy, initiated prior to reperfusion, can reduce MI size and prevent adverse post‐MI LV remodeling.

show abstract

“…Meanwhile, the medication has not been changed. At admission, he presented himself in a good condition (according to New York Heart Association class II 6) but avoided intense physical activity fearing a new arrhythmia. The left ventricular (LV) systolic function was significantly reduced (ejection fraction 35%).…”

Section: Case Reportmentioning

confidence: 99%

Catheter ablation of hemodynamically unstable ventricular tachycardia in ischemic cardiomyopathy using high‐resolution mapping

Kaiser

Jularic

Akbulak

et al. 2017

Clinical Case Reports

View full text Add to dashboard Cite

Key Clinical MessageCatheter ablation is a recommended therapy option for ventricular tachycardia (VT). The antegrade transseptal approach for targeting VT with left ventricular origin is feasible with the high‐resolution basket catheter. High‐resolution mapping offers the potential to quickly acquire detailed voltage and activation maps. This may help to identify the crucial VT‐substrate even in patients with huge scar areas and hemodynamically unstable VT.

show abstract

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012

Cited by 2,121 publications

References 282 publications

Mesenchymal stem cell‐loaded cardiac patch promotes epicardial activation and repair of the infarcted myocardium

Mesenchymal stem cell‐loaded cardiac patch promotes epicardial activation and repair of the infarcted myocardium

Mineralocorticoid Receptor Antagonist Pretreatment to MINIMISE Reperfusion Injury After ST‐Elevation Myocardial Infarction (The MINIMISE STEMI Trial): Rationale and Study Design

Catheter ablation of hemodynamically unstable ventricular tachycardia in ischemic cardiomyopathy using high‐resolution mapping

Contact Info

Product

Resources

About